Diagnostics · CRISPR molecular detection
VedaBio
A San Diego company building a CRISPR test that removes the copying step at the heart of PCR. The chemistry is published in PNAS. The product is not cleared by the FDA and is not for sale.
Two microliters and ten minutes
The method section reads like a kitchen note. Two microliters of sample go into nine microliters of master mix. The tube goes into a QuantStudio 3. Ten minutes, with a fluorescence reading every minute.
That is the whole assay in the March 2025 paper in the Proceedings of the National Academy of Sciences that first described VedaBio’s chemistry in a peer reviewed journal. No thermal cycling, no copying of the target. The paper reports that it can tell MRSA, methicillin sensitive S. aureus, Escherichia coli and hepatitis B virus apart in spiked whole blood.
The number the field has been stuck on is sensitivity. A single Cas12a reaction, the standard CRISPR detection trick, runs out of road around the picomolar range. Clinical work wants femtomolar or attomolar. That gap is why nearly every CRISPR test built so far still copies the target first, which as the PNAS authors put it makes the CRISPR step largely redundant.
The Cascade reaction closes the gap by feeding itself. A first ribonucleoprotein finds the target and starts cutting. What it cuts includes a blocked molecule that releases a new activator, which switches on a second, far more abundant ribonucleoprotein, which cuts more blocked molecules. The signal, not the target, is what multiplies.
Where the test would go
VedaBio is not aiming at hospital labs. It is aiming at urgent care, a setting that has roughly doubled in a decade to more than 15,000 US centers and about 200 million visits a year, and where roughly a third of visits are respiratory.
What those clinics can run today is an antigen test for influenza, COVID and sometimes RSV. Everything else goes home unnamed. The company says that in hospitals four of five patients get an actionable result from syndromic testing, while in decentralized settings only about one in five do. That figure comes from a VedaBio release, not an independent study.
A dean, a graduate student, and a name change
Anurup Ganguli was finishing a PhD at the University of Illinois Urbana-Champaign, reading CRISPR detection preprints out of the Doudna and Zhang labs, when he fixed on one fact about the field: every molecular detection platform since PCR arrived in 1983 had started by copying the target. His adviser was Rashid Bashir, now dean of the Grainger College of Engineering at Illinois. The two founded the company in 2021.
It was not called VedaBio then. The San Diego Business Journal reported in 2025 and again in 2026 that the company was founded as LabSimply, a spin out of Illinois, before the name change and the move west. Ganguli brought seven people to San Diego; by the October 2023 launch there were 26. Today the headcount is about 20.
The leadership changed too. Ganguli was co-founder and chief executive at launch, with Frederic Sweeney, a venture partner at lead investor OMX Ventures who had been sent in to do diligence and stayed, as president and chief operating officer. In March 2024 Sweeney became chief executive. The company’s current about page carries one leadership biography, his. It does not mention Ganguli, whose name is still on most of the patents.
The clock, from one minute to ten
When VedaBio came out of stealth on October 17, 2023, the claim was an analytical turnaround time of less than one minute, at room temperature, with PCR level accuracy. GenomeWeb noted that the team had no published peer reviewed descriptions of the technology, and pointed to a patent figure showing room temperature detection of three copies of MRSA DNA in one minute.
The published work landed later and reads more conservatively. The 2025 PNAS paper reports a signal to noise ratio above 1.3 within ten minutes at attomolar levels. A follow up in May 2026 adds a dual blocking design, keeps the ten minute reaction, reports single copy sensitivity, and detects MRSA from whole blood in under 40 minutes including sample preparation. The company now describes an answer in under ten minutes including hands on time.
Two things changed in September 2025. VedaBio took a non exclusive license to Mammoth Biosciences diagnostic CRISPR intellectual property, which Sweeney told 360Dx let the company collapse its two enzyme system down to one. Siemens Healthineers signed a strategic agreement alongside a Series A extension, the two together worth up to $25 million.
What is proven, and what is still claimed
| Evidence | What the record shows | Source type |
|---|---|---|
| Peer reviewed chemistry | PNAS, March 18, 2025. Lim, Van, Koprowski, Wester, Valera and Bashir report a CRISPR-Cascade assay reaching atto-molar levels in 10 minutes, with an OR gate detecting MRSA, MSSA, E. coli and HBV from whole blood. Competing interests statement: R.B. has financial interests in VedaBio, Inc. | Public record |
| Follow up paper | PNAS, May 26, 2026, same group. A dual blocking design cages both the guide RNA and the trigger DNA, cutting leakage about 3 to 18 fold, with single copy sensitivity and MRSA detection from whole blood in under 40 minutes. | Public record |
| Who the papers belong to | No PubMed indexed paper carries a VedaBio affiliation. The company appears only in competing interest statements on University of Illinois papers. A March 2026 bioRxiv preprint puts it plainly: Rashid Bashir is the co-founder of VedaBio, Inc. | Public record |
| Patents | 20 granted US patents assigned to VedaBio, Inc., first issued November 21, 2023, most recent February 17, 2026. Two are co-assigned with The Board of Trustees of the University of Illinois. | Public record |
| FDA status | No 510(k), PMA, emergency use authorization, registration or listing under VedaBio or LabSimply in openFDA as of September 23, 2026. The company states the system is investigational and has not been cleared, authorized or approved. | Public record |
| Clinical studies | No registered study on ClinicalTrials.gov. The company says clinical data has been generated on a product feature ready cartridge and a prototype instrument. That data has not been published. | Not found |
| Speed, as claimed over time | 2023: an analytical turnaround of less than one minute. 2025 and 2026 published work: 10 minutes for the reaction, under 40 minutes end to end from blood. 2026 marketing: an answer in under 10 minutes including hands on time. | Claim narrowed |
| Partners | Mammoth Biosciences, non exclusive diagnostic license, September 9, 2025. Siemens Healthineers, strategic agreement and Series A extension, September 23, 2025. UCP Merchant Medicine, multi year channel engagement, September 1, 2026. | Partner-stated |
Read plainly: the chemistry is real, published, and carried across two PNAS papers and a modeling preprint. The product is not. There is no cleared device, no registered trial, and no published clinical performance. The papers come from the co-founder’s academic lab, which is a normal route for a spin out and also a reason to read them as evidence about a chemistry rather than about a cartridge.
What to watch
- An FDA submission. In September 2025 the stated target was the next few years; the September 2026 plan puts most pre launch work in the following 18 months, with commercial preparation tentatively in the second half of 2027.
- Clinical performance data on the cartridge and instrument, in a paper or a conference presentation rather than a release.
- A Series B. Sweeney said in 2025 it could come as soon as the second half of 2026, and in September 2026 the company said it plans to launch one in the immediate future.
In their words
“With the CRISPR Cascade reaction, we have unlocked the true power of CRISPR with a platform that delivers near-instant molecular detection of highly multiplexed analytes with best-in-class accuracy, all without the need for target amplification.”
Anurup Ganguli, co-founder and then CEO, launch release, October 2023 · Company release
“you can get rid of the amplification step while capturing state-of-the-art gold standard accuracy”
Anurup Ganguli, to GEN, October 2023 · Interview
“They’ll test you for flu, for COVID, maybe RSV if you’re lucky, but there’s 80% of these other pathogens that are not tested for.”
Frederic Sweeney, CEO, San Diego Business Journal, September 2026 · Independent
“The team here has built a billion-dollar business in syndromic testing, and we know this market cold.”
Frederic Sweeney, to 360Dx, September 2025 · Interview
“If I blindfold you and switch to our device from a Sofia device, from the workflow perspective, you will see no difference.”
Frederic Sweeney, to 360Dx, September 2025 · Interview
“A lot of very good diagnostic platforms have failed, and not because of the science.”
Frederic Sweeney, UCP Merchant Medicine release, September 2026 · Company release
Related companies
Sources
- Public recordAmplification-free, OR-gated CRISPR-Cascade reaction in blood samples
- Public recordAmplification-free dual-blocking autocatalytic CRISPR-Cascade
- Public recordPatents assigned to VedaBio, Inc., 20 grants listed
- Public recordEDGAR company search and full text search for VedaBio, no results
- Public recordopenFDA 510(k), PMA and listing queries, no results
- Public recordClinicalTrials.gov, NIH RePORTER and NSF award searches, no results
- IndependentNew CRISPR diagnostic player VedaBio emerges with $40M start
- IndependentStartup VedaBio Pushing Boundaries of Nucleic Acid Detection
- IndependentAmped Up: VedaBio Launches with $40+ Million
- IndependentVedaBio Accelerating Amplification-Free Syndromic POC MDx
- IndependentVedaBio Focused on Product Development with New Strategic Partnerships
- IndependentVedaBio Bringing Molecular Diagnostics Platform to Urgent Care
- IndependentSiemens Healthineers enters CRISPR diagnostics space
- CompanyVedaBio Launches with Over $40 Million
- CompanyVedaBio Strengthens Management Team
- CompanyVedaBio Selects UCP Merchant Medicine for Urgent Care
- CompanyVedaBio website, platform, about and press pages
Profile researched and written by Healthcare Discovery. Last updated September 29, 2026.
